StockNews.com Upgrades Royalty Pharma (NASDAQ:RPRX) to “Buy”

Royalty Pharma (NASDAQ:RPRX) was upgraded by StockNews.com from a “hold” rating to a “buy” rating in a research note issued on Tuesday.

Several other equities research analysts have also recently issued reports on the stock. Morgan Stanley raised their price objective on shares of Royalty Pharma from $48.00 to $51.00 and gave the stock an “overweight” rating in a research report on Thursday, July 11th. The Goldman Sachs Group lifted their price target on shares of Royalty Pharma from $50.00 to $51.00 and gave the company a “buy” rating in a research report on Wednesday, August 14th. Finally, UBS Group cut Royalty Pharma from a “buy” rating to a “neutral” rating and set a $28.00 price objective on the stock. in a report on Monday, June 3rd. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $42.00.

Royalty Pharma Price Performance

RPRX stock opened at $28.21 on Tuesday. Royalty Pharma has a 1 year low of $25.20 and a 1 year high of $31.66. The company has a debt-to-equity ratio of 0.78, a current ratio of 9.35 and a quick ratio of 9.35. The firm has a market capitalization of $16.85 billion, a PE ratio of 21.05, a price-to-earnings-growth ratio of 4.06 and a beta of 0.46. The business has a 50 day simple moving average of $27.95 and a 200-day simple moving average of $28.02.

Royalty Pharma (NASDAQ:RPRX) last issued its earnings results on Thursday, August 8th. The biopharmaceutical company reported $0.96 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.95 by $0.01. Royalty Pharma had a return on equity of 23.61% and a net margin of 30.08%. The company had revenue of $537.00 million during the quarter, compared to analysts’ expectations of $600.83 million. During the same period in the prior year, the business earned $0.85 EPS. Equities research analysts anticipate that Royalty Pharma will post 4.04 earnings per share for the current fiscal year.

Institutional Trading of Royalty Pharma

Several institutional investors have recently added to or reduced their stakes in RPRX. Versant Capital Management Inc boosted its position in shares of Royalty Pharma by 5,215.0% during the second quarter. Versant Capital Management Inc now owns 1,063 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 1,043 shares during the period. Gladius Capital Management LP purchased a new position in Royalty Pharma during the 2nd quarter valued at about $32,000. Fidelis Capital Partners LLC acquired a new position in Royalty Pharma in the 1st quarter valued at about $46,000. GAMMA Investing LLC grew its position in Royalty Pharma by 172.5% in the 1st quarter. GAMMA Investing LLC now owns 1,638 shares of the biopharmaceutical company’s stock valued at $50,000 after acquiring an additional 1,037 shares in the last quarter. Finally, EverSource Wealth Advisors LLC increased its stake in Royalty Pharma by 79.8% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,807 shares of the biopharmaceutical company’s stock worth $51,000 after purchasing an additional 802 shares during the period. Institutional investors and hedge funds own 54.35% of the company’s stock.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.